Salute e Benessere

Bioburden Testing Market worth $2.59 billion by 2031 Owing To Increasing Demand…

Market Dynamics: Market Dynamics : The bioburden testing market is projected to experience significant growth due to the increasing demand for quality assurance and safety measures in various industries. The rising awareness about the importance of bioburden testing in preventing contamination and ensuring product safety is driving the market growth. Bioburden testing helps in determining the microbial load on a product or raw material, thereby enabling manufacturers to maintain the quality...
PR Newswire
15/02/2024

Hernia Repair Market Worth $5.1 Billion | MarketsandMarkets™

Browse in-depth TOC on "Hernia Repair Market" Browse in-depth TOC on "Hernia Repair Market" 204 - Tables41 - Figures230 - Pages Hernia Repair Market Scope: The mesh segment is to register a significant growth rate over the forecast period of 2024-2029. Based on the product, over the forecast period of 2024-2029, the mesh segment is to register a significant growth rate. The hernia repair product market is segmented into mesh, sutures and mesh fixators. The hernia...
PR Newswire
15/02/2024

Saudi Arabia Health Tech Market Booms: $5.7 Billion by 2027 Fueled by Innovation…

Market Overview: Redefining Healthcare, Empowering Lives Market Overview: Redefining Healthcare, Empowering Lives Beyond simply offering digital solutions, the Saudi health tech market plays a crucial role in improving healthcare access, enhancing patient experience, and driving cost efficiencies within the healthcare system. In 2022, the market reached a size of $2.5 billion , and it's on track for remarkable growth, driven by: Interested to Know More about this Report, ...
PR Newswire
15/02/2024

Albumin Market to Reach $9.9 billion, Globally, by 2032 at 6.2% CAGR: Allied…

Request Sample of the Report on Albumin Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/2583 Request Sample of the Report on Albumin Market Forecast 2032-https://www.alliedmarketresearch.com/request-sample/2583 Prime determinants of growth Surge in healthcare infrastructure, rise in number of surgical procedures, and increase in awareness regarding the use of albumin are the factors that drive the growth of the global albumin market. However, stringent...
PR Newswire
15/02/2024

Planetree's Person-Centered Care Certification Standards Achieve International…

"Healthcare organizations around the world turn to Planetree's Person-Centered Care Certification® standards as the benchmark of excellence and the framework for translating PCC concepts into reality," said Michael Giuliano, Planetree's President. "Our rigorous evaluation process rooted in the lived experiences of patients, families and staff sends a clear message that our Certified sites have met the highest international standards for person-centered excellence. Similarly, this…
PR Newswire
15/02/2024

Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces…

A Binding LOI has been executed: GEDiCube will acquire 75% of Cyclomics at Closing. Expected breakthroughs by combining technologies in (early) cancer detection and recurrence of cancer with a single vial of blood. Cyclomics' 4th generation liquid biopsy genomics platform is the first truly “Omni-Omic” blood test ready for AI application.GEDiCube's award-winning AI is developing high-performance biomarker panels for 13 different cancers. GEDiCube's partnership with...
Nasdaq GlobeNewswire
15/02/2024

Dragonfly Announces Clinical Collaboration Exploring Combinations of Dragonfly's…

"DF1001 is the first of eight Dragonfly-developed drugs in the clinic and has shown clinical benefit in mBC, NSCLC and colorectal cancer (CRC) in a heterogeneous Phase 1 population with 22% RECIST responders and 39% clinical benefit in mBC patients at active dose levels, with no DLTs, even in a heavily-pre-treated population," said Joseph Eid, Dragonfly President of R&D. "It has been demonstrated to be well tolerated across all dose levels in the Phase 1 study as monotherapy…
PR Newswire
15/02/2024

Hearing loss company Acousia announces first patient enrolled in its Phase 2…

In the double-blind, randomized PROHEAR-Study, patients with testicular cancer receive transtympanic injections of ACOU085 in one ear and a placebo in the contralateral ear prior to each chemotherapy cycle, as such each patient serves as his own control. The PROHEAR-Study is being conducted at major university clinics across Germany and has been formally endorsed by the Study Group of the German Society of Otorhinolaryngology (DSZ-HNO). In the double-blind, randomized PROHEAR-Study, patients...
PR Newswire
15/02/2024

AMO Pharma Announces Collaboration with Population Health Research Institute to…

"It can be a helpless feeling to carry a gene for ACM and know that, no matter how you live your life, you may someday develop a deadly form of heart disease," said Jason Roberts, scientist at PHRI and TaRGET study principal investigator, adding, "Encouraged by earlier studies in animal models, we are hopeful that tideglusib may serve as an effective treatment that can dramatically improve the health of people living with ACM. The TaRGET trial is a critical first step in…
PR Newswire
15/02/2024

Press Release: Phase 2 data published in NEJM show potential of frexalimab as…

Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MSHigh-dose frexalimab significantly reduced disease activity, demonstrating 89% reduction in new brain lesions Phase 3 trials in relapsing MS and non-relapsing secondary progressive MS currently underwayParis, February 15, 2024.The New England Journal of Medicinepublishedresults from a positive Phase 2 clinical trial demonstrating frexalimab significantly slowed disease activity...
Nasdaq GlobeNewswire
15/02/2024

Inside information made public: Nanoform Wins R&D Grant of EUR 4.3M for Research…

Nanoform has established a unique capability to consistently manufacture particles at less than 100 nanometers, and has developed a deep understanding of nanoparticle interactions, and their performance in pharmaceutical formulations. This grant gives an opportunity to generate deep knowledge about nanoparticle behavior in formulation- and pharmaceutical sciences and to create new intellectual property. Nanoform has established a unique capability to consistently manufacture particles at less...
PR Newswire
15/02/2024

Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to…

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has reached settlement agreements with Johnson & Johnson in Japan, Canada and in the European Economic Area (EEA) for AVT04, a biosimilar to Stelara® (ustekinumab). Regulatory approval for AVT04 in these markets has already been granted. Market applications for AVT04 are currently pending in additional global markets,...
Nasdaq GlobeNewswire
15/02/2024

King Faisal Specialist Hospital & Research Centre Holds Firm as Global…

RIYADH, Saudi Arabia, Feb.15, 2024(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH&RC) has once again secured its position for the second consecutive year as a global leader in healthcare and number one in the Middle East and Africa, ranking 20 thglobally among the leading healthcare institutions in the Brand Finance Global Top 250 Hospitals 2024 report. KFSH&RC continues to stand at the forefront both locally and regionally, underlining its...
Nasdaq GlobeNewswire
15/02/2024

Notice to Convene the Annual General Meeting of Genmab A/S

Company Announcement Genmab A/S to hold Annual General Meeting on Wednesday March 13, 2024COPENHAGEN, Denmark; February 15, 2024 –Genmab A/S(Nasdaq: GMAB) summons the Annual General Meeting on Wednesday, March 13, 2024, at 2:00 PM CET at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, DK-1560 Copenhagen V, Denmark. The notice for the Annual General Meeting, including Appendix 1: Candidates for the Board of Directors, and Appendix 2: Proposed new Remuneration Policy is...
Nasdaq GlobeNewswire
15/02/2024

Kim Byoung Joon LEDAS Varicose Vein Clinic Becomes the First Organization to be…

Kim Byoung Joon LEDAS Varicose Vein Clinic (LEDAS) is known for its excellent vascular treatment services for varicose veins, using the latest technologies such as EVLA, ultrasound-guided sclerotherapy, and sclerotherapy. It is the first varicose vein specialty clinic in Korea to be certified by GHA, emphasizing its commitment to quality and patient experience. Kim Byoung Joon LEDAS Varicose Vein Clinic (LEDAS) is known for its excellent vascular treatment services for varicose veins, using…
PR Newswire
15/02/2024

Pharmaoffer combats medicine shortages by unveiling expansion into CDMOs…

This new activity positions Pharmaoffer as an all-in-one digital solution, bridging the gap between seekers and providers of pharma products and services worldwide. Pharmaoffer extends its user-friendly interface and transparency to this new domain, facilitating efficient and direct communication between parties. This new activity positions Pharmaoffer as an all-in-one digital solution, bridging the gap between seekers and providers of pharma products and services worldwide. Pharmaoffer…
PR Newswire
15/02/2024

Pierre Fabre Laboratories and the EspeRare Foundation to be honored with the…

This distinction recognises Pierre Fabre and the EspeRare Foundation's collaboration with the Ectodermal Dysplasia (ED) patient community. Indeed, they have been working in synergy from the early stage and all along treatment development, in order to bring what could become the first prenatal therapy for X-linked hypohidrotic ectodermal dysplasia (XLHED). This distinction recognises Pierre Fabre and the EspeRare Foundation's collaboration with the Ectodermal Dysplasia (ED) patient community...
PR Newswire
15/02/2024

Ipsen S.A. publishes its 2023 Consolidated Financial Statements

Ipsen S.A. - 2023 Consolidated Financial Statements Attachment Ipsen - 2023 Consolidated Financial Statements
Nasdaq GlobeNewswire
15/02/2024

Diamyd Medical receives U.S. FDA Fast Track designation for Diamyd®

The treatment paradigm for Type 1 Diabetes is shifting towards precision medicine, due to inadequacy of current treatment options that are characterized by a failure to consistently achieve glycemic targets as well as the prevalence of short- and and long-term complications. This highlights the urgent need for new therapeutic approaches like the antigen-specific therapy Diamyd® that has shown promising results in preserving pancreatic beta cell function and improving glycemic control in…
PR Newswire
15/02/2024

Prof. Dr. Karsten Hemmrich Appointed as CEO of POLYTECH Health & Aesthetics

"I am honoured to lead POLYTECH into its next phase of innovation and expansion. With a distinguished team and a robust pipeline of products, our future is exceedingly promising", said Prof. Hemmrich. "I am honoured to lead POLYTECH into its next phase of innovation and expansion. With a distinguished team and a robust pipeline of products, our future is exceedingly promising" , said Prof. Hemmrich. Bringing a wealth of experience from his tenure as Global Vice President at…
PR Newswire
15/02/2024

Introducing APPLE & BEARS Leisure Trade Platform: Catering for the Hoteliers…

Environmental Commitment for a Sustainable Future: Environmental Commitment for a Sustainable Future: At the heart ofAPPLE & BEARS ethos lies a steadfast commitment to environmental responsibility. The Leisure Trade Platform takes a bold step by introducing refillable body care products, a significant move towards reducing environmental impact and fostering a sustainable future. Meticulously Crafted Gender-Neutral Amenities: Guests are invited to indulge in luxury with APPLE...
PR Newswire
15/02/2024

Navamedic Q4 and full year 2023: A year marked by new records and transformative…

Operating results (EBIT) amounted to NOK 23.6 million, compared to NOK 44.4 million in 2022. Operating costs were higher than in 2022, mostly due to continued investments in growth initiatives. Also included in the EBITDA is a negative contribution of 4.8 MNOK from the Sensidose business. Operating results (EBIT) amounted toNOK 23.6 million, compared toNOK 44.4 millionin 2022. Operating costs were higher than in 2022, mostly due to continued investments in growth initiatives. Also...
PR Newswire
15/02/2024

Implantica's RefluxStop™ now available in Munich

Prof. Mussack says, "I appreciate how RefluxStop™ restores the body's natural anatomy to solve the root problem of GERD. As a minimally invasive procedure that does not encircle the food passageway, RefluxStop™ allows me to offer a surgical solution to patients who previously were not candidates for surgery, which is incredibly exciting." Prof. Mussack says, "I appreciate how RefluxStop™ restores the body's natural anatomy to solve the root problem of GERD. As a minimally invasive…
PR Newswire
15/02/2024

dsm-firmenich to separate out Animal Nutrition & Health business from the Group

A separation would enable dsm-firmenich to strengthen its position as a world-leader in nutrition, health, and beauty. By fully focusing on Perfumery & Beauty (P&B); Taste, Texture & Health (TTH); and Health, Nutrition & Care (HNC), the Company can further develop its complementary world-class scientific research, technologies and manufacturing excellence. Full focus on these businesses is expected to enhance their commercial potential and synergies, supporting an attractive and…
PR Newswire
15/02/2024
Altri  Comunicati